Evidence map›Paper›PMID 19008265›Full record

SynthesisBMJ (Clinical research ed.)2008

Effect of fibre, antispasmodics, and peppermint oil in the treatment of irritable bowel syndrome: systematic review and meta-analysis.

Alexander C Ford, Nicholas J Talley, Brennan M R Spiegel, Amy E Foxx-Orenstein, Lawrence Schiller, Eamonn M M Quigley, Paul Moayyedi

Erratum issued Registry-linked trialOpen access · hybridAbstract readComparative StudyMeta-AnalysisSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in BMJ (Clinical research ed.), 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to trial NCT02716285 (Peppermint Oil for the Treatment of Irritable Bowel Syndrome), which is not on this map. Cited by 160 papers, 15 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
160citing papers in PubMed, 15 pooled it
22.1field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02716285 phase3completednot on this mapstarted 2016, after this paper: background citation

Peppermint Oil for the Treatment of Irritable Bowel Syndrome: Optimizing Therapeutic Strategies Using Targeted Delivery

TypeinterventionalSponsorMaastricht University Medical CenterRan2016 to 2018Enrolled190ConditionsIrritable Bowel Syndrome, Abdominal Pain, Colonic Diseases, FunctionalArmsIleocolonic release peppermint oil, Placebo, Small intestinal release peppermint oil
3 · Its place in the literature

Who cites it

160 citing papers in PubMed, 15 syntheses or guidelines pooled it, 561 citations in OpenAlex.

  1. Pooled it
  2. Guideline
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Effectiveness of Menthacarin on symptoms of irritable bowel syndrome.Wiener medizinische Wochenschrift (1946) · 2019
    Pooled it
  7. Pooled it
  8. Guideline
  9. Pooled it
  10. Pooled it
  11. Guideline
  12. Pooled it
  13. Irritable bowel syndrome.BMJ clinical evidence · 2012
    Pooled it
  14. Pooled it
  15. Irritable bowel syndrome.BMJ clinical evidence · 2010
    Pooled it
  16. Trial
  17. Trial
  18. Psyllium Fiber Reduces Abdominal Pain in Children With Irritable Bowel Syndrome in a Randomized, Double-Blind Trial.Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association · 2017
    Trial
  19. Trial
  20. Trial

100 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors at 7 institutions in 3 countries.

Alexander C FordGastroenterology Division, McMaster University, Health Sciences Centre, 1200 Main Street West, Hamilton, ON, L8N 3Z5, Canada. alexf12399@yahoo.com
Nicholas J Talley
Brennan M R Spiegel
Amy E Foxx-Orenstein
Lawrence Schiller
Eamonn M M Quigley
Paul Moayyedi
Baylor University Medical Center · USCork University Hospital · IEHealth Sciences Centre · CAMayo Clinic in Arizona · USMayo Clinic in Florida · USMcMaster University · CAVA Greater Los Angeles Healthcare System · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo determine the effect of fibre, antispasmodics, and peppermint oil in the treatment of irritable bowel syndrome.

designSystematic review and meta-analysis of randomised controlled trials. DATA SOURCES: Medline, Embase, and the Cochrane controlled trials register up to April 2008. Review methods Randomised controlled trials comparing fibre, antispasmodics, and peppermint oil with placebo or no treatment in adults with irritable bowel syndrome were eligible for inclusion. The minimum duration of therapy considered was one week, and studies had to report either a global assessment of cure or improvement in symptoms, or cure of or improvement in abdominal pain, after treatment. A random effects model was used to pool data on symptoms, and the effect of therapy compared with placebo or no treatment was reported as the relative risk (95% confidence interval) of symptoms persisting.

results12 studies compared fibre with placebo or no treatment in 591 patients (relative risk of persistent symptoms 0.87, 95% confidence interval 0.76 to 1.00). This effect was limited to ispaghula (0.78, 0.63 to 0.96). Twenty two trials compared antispasmodics with placebo in 1778 patients (0.68, 0.57 to 0.81). Various antispasmodics were studied, but otilonium (four trials, 435 patients, relative risk of persistent symptoms 0.55, 0.31 to 0.97) and hyoscine (three trials, 426 patients, 0.63, 0.51 to 0.78) showed consistent evidence of efficacy. Four trials compared peppermint oil with placebo in 392 patients (0.43, 0.32 to 0.59).

conclusionFibre, antispasmodics, and peppermint oil were all more effective than placebo in the treatment of irritable bowel syndrome.

Indexed as

AdultDietary FiberHumansIrritable Bowel SyndromeMentha piperitaParasympatholyticsPlant OilsRandomized Controlled Trials as TopicTreatment OutcomeUnited StatesDietary FiberParasympatholyticspeppermint oilPlant Oils

Identifiers

PMID19008265
PMCPMC2583392
OpenAlexW2033600566

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.